PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer

• The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases
• The treatment delivered an ORR of nearly 78%, compared to 35% in a similar trial without the drug.
• Two-year survival exceeded 80%, more than double the 35 - 40% seen in the comparison group.

Shares of PDS Biotechnology (PDSB) surged 24% on Wednesday to hit their highest levels since Aug. 27, 2025, after the biotech firm reported promising Phase 2 trial results for its therapy to treat metastatic colorectal cancer.

PDSB stock recorded its biggest intraday gains since May 26, 2023.

Early Results Show Strong Response Rate

PDS Biotechnology said its investigational immunotherapy, PDS01ADC, demonstrated strong efficacy in a cohort of colorectal cancer patients. In the Phase 2 trial, the treatment delivered an objective response rate (ORR) of nearly 78%, compared to 35% in a similar trial without the drug. Two-year survival exceeded 80%, more than double the 35% to 40% seen in the comparison group.

The trial focused on patients with microsatellite stable (MSS) or mismatch repair-proficient (pMMR) metastatic colorectal cancer with liver metastases. The results were published in the Journal of Clinical Oncology (JCO) Oncology Advances on March 10, 2026, the company said.

“These early results showing strong tumor response rates and promising patient survival are encouraging and support our approach of subcutaneously administering PDS01ADC to activate the immune system against the cancer,” said Frank Bedu-Addo, President and CEO of PDS Biotech.

How Did Retail Traders React?

One user wondered about a potential buyout, saying the company is “starting to be attractive to the big boys.”

Another user called the update “great news.”

Last month, PDS Biotechnology announced updates to its Phase 3 VERSATILE-003 trial, adding progression-free survival as an interim primary endpoint, which could support faster approval of PDS0101 in HPV16-related head and neck cancer.

The company also secured new patents in the U.S. and Japan, extending protection into the 2040s.

Year-to-date, the stock has gained 47%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.